Cost-Utility Analyses of Natalizumab Versus Interferon Beta-1a 44 Mcg for Rapidly Evolving Severe Relapsing-Remitting Multiple Sclerosis (RESRRMS) Patients in Brazil
Nov 1, 2013, 00:00
10.1016/j.jval.2013.08.1834
https://www.valueinhealthjournal.com/article/S1098-3015(13)03739-X/fulltext
Title :
Cost-Utility Analyses of Natalizumab Versus Interferon Beta-1a 44 Mcg for Rapidly Evolving Severe Relapsing-Remitting Multiple Sclerosis (RESRRMS) Patients in Brazil
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(13)03739-X&doi=10.1016/j.jval.2013.08.1834
First page :
A624
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
1672